Back to Search
Start Over
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study
- Source :
- British Journal of Haematology, British Journal of Haematology, 2018, 183 (1), pp.76-86. ⟨10.1111/bjh.15513⟩, British journal of haematology, (2018)
- Publication Year :
- 2018
- Publisher :
- HAL CCSD, 2018.
-
Abstract
- International audience; The treatment of low-tumour burden follicular lymphoma (LTBFL) remains a challenge. Rituximab-based strategies may be improved by adding chemotherapy. This Lymphoma Study Association multicentre phase II study assessed rituximab and bendamustine in 63 patients with untreated LTBFL who were aged over 60years old and had a follicular lymphoma International Prognostic Index (FLIPI) score ≥2. Induction comprised 4 weekly cycles of rituximab 375mg/m intravenously combined with 2 cycles of bendamustine 90mg/m days 1-2 with a 28-day interval, followed by twelve cycles of 375mg/m rituximab maintenance therapy every 8weeks. The primary endpoint was complete response (CR)/unconfirmed CR (CRu), at 12weeks. Median age was 67·4years and median FLIPI was 3. Ultimately, 18 patients (29%) had high tumour burden according to Groupe d'Etude des Lymphomes Folliculaires criteria. The 12-week CR/CRu rate was 54·0% and the overall response rate was 93·7%. Surprisingly, 3 patients died during maintenance (2 sepsis, 1 neoplasm). Progression-free survival was 85·4% at 24months. In LTBFL patients with FLIPI ≥2, two cycles of rituximab and bendamustine result in a CR rate of 54·0%. However, the treatment-related deaths observed do not allow this regimen to be recommended for LTBFL patients aged over 60years. EudraCT: 2010-020757-14; ClinicalTrials.gov: NCT01313611.
- Subjects :
- Bendamustine
Male
medicine.medical_specialty
Efficacy
[SDV]Life Sciences [q-bio]
efficacy
Follicular lymphoma
Phases of clinical research
Gastroenterology
Maintenance Chemotherapy
03 medical and health sciences
0302 clinical medicine
International Prognostic Index
rituximab
Maintenance therapy
follicular lymphoma
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Bendamustine Hydrochloride
Humans
bendamustine
Lymphoma, Follicular
Aged
Aged, 80 and over
tolerance
business.industry
Remission Induction
Hematology
Middle Aged
medicine.disease
Survival Analysis
3. Good health
Lymphoma
Tumor Burden
Regimen
Treatment Outcome
030220 oncology & carcinogenesis
Rituximab
Female
business
Tolerance
030215 immunology
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 13652141 and 00071048
- Database :
- OpenAIRE
- Journal :
- British Journal of Haematology, British Journal of Haematology, 2018, 183 (1), pp.76-86. ⟨10.1111/bjh.15513⟩, British journal of haematology, (2018)
- Accession number :
- edsair.doi.dedup.....a81f97a0cb5a1b9b0dc906c8534771d8